Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

DraftKings (NASDAQ: DKNG) is forecasting robust growth in revenue and profitability in 2025. Read More: Earn up to $845 cash ...

The overall value in Carnival stock is compelling here, making it more a buy than a sell or even a hold. This was an industry ...

Stodgy tobacco stock Altria Group ( MO 0.18%), most known for selling Marlboro cigarettes in the U.S. and paying hefty ...

The FFHH crew previews Week 10, highlighting three exciting matchups, including a Monday Night Football battle between Tyreek ...

In the last one year, the stock has gained 113 per cent and in the last one month the stock has been moving in a range of Rs ...

Entergy has strong growth potential but appears overvalued. See why ETR stock’s favorable regulatory environment and dividend ...

Here's the complete list of investment and trading ideas for the day. Buy Sansera Engineering shares in the cash segment for ...

Chandan Taparia has recommended three stocks to buy today – Infosys, Bank of Baroda, and Power Finance Corporation ...

AstraZeneca's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected ...

Over the past 30 years, Realty Income generated a total return of 4,960% with reinvested dividends, which easily beat the S&P ...